Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Chimeric antigen receptors targeting epidermal growth factor receptor variant III

Chimeric antigen receptors targeting epidermal growth factor receptor variant III

US Patent 11267892 · Granted Mar 8, 2022

Estimated economic value: $1,033,796,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Polymer nanoparticle compositions for in vivo expression of polypeptides2025
Method of treatment using anti-CD19 rituximab-resistant chimeric antigen recepto2025
Protease-activating CD45-gate CAR2025
Chimeric antigen receptors targeting FLT32025
Chimeric antigen receptors with enhanced signaling and activities and uses there2025
Methods of manufacturing allogeneic CAR T cells2024
Chimeric antigen receptors targeting CD702024
Chimeric antigen receptors targeting CD702024
Universal anti-CD22 chimeric antigen receptor engineered immune cells2024
Constitutively active chimeric cytokine receptors2024
BCMA CAR-T cells with enhanced activities2024
Antibodies specific for CD70 and their uses2024